Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Eli Lilly and its wholly owned subsidiary, Avid Radiopharmaceuticals related to their new drug application (NDA) for Amyvid (florbetapir F 18 injection).
Subscribe to our email newsletter
Avid, a wholly-owned subsidiary of Eli Lilly. Lilly acquired Avid Radiopharmaceuticals in December 2010.
Amyvid is a molecular imaging agent under investigation for Positron Emission Tomography (PET) imaging of beta-amyloid plaque in the brain.
Avid claims that Amyvid is its lead candidate and was the first beta-amyloid imaging compound to enter multi-center, investigational new drug (IND) clinical studies in the US.
Lilly brand director for Amyvid Wei-Li Shao said Lilly and Avid have been engaged in an active and ongoing dialogue with the FDA. They remain confident in the data submission package for Amyvid,"